Abstract 414P
Background
Gastrointestinal stromal tumours (GIST) are the most common mesenchymal tumours originating from the interstitial cells of Cajal and differentiates from other mesenchymal neoplasm by expression of CD117 oncogene. Most GISTs are found in the stomach followed by small bowels. Using NIH risk groups, the low risk GISTs were less frequent and the highest risk group was the commonest one. The main aim of this study was to evaluate demographic data , assess risk groups and study the clinical outcomes among GIST patients attending the Medical Oncology department , Yangon General hospital from 2015 to 2017.
Methods
Retrospective descriptive study.
Results
Among 73 patients, male: female is 2:1. The most common age group was 51-60 years. Regarding tumor site, small intestine was the most common site and the most patients were found to have tumor size between 11 to 20cm. According to TNM staging, 48% of patients were stage III. By using NIH risk stratification, it was found that 84% of patients were in high risk group. Tumour resection was performed in 77.8% and palliative resection was done in 22.2% of patients. CD117 immunostaining was performed in all 73 patients but CD117 expression was found in 69 patients. 4 patients were CD117 negative but CD34 positive. Therapy with imatinib (400–600mg) was given in 73 patients. Among them, 13 patients was occurred loss follow-up and could not assessed due to social and transportation difficulties. Three patients were expired due to disease progression. 57 patients were alive and taken imatinib up to 3 year. We initially assessed with USG and if there was suspected lesion in USG, we did further advanced imaging like CT. Among these patients who took imatinib up to 3 years, 5 patients was found to have recurrence and change to second line therapy. 52 out of 73 patients remained clinically stable and no recurrence up to 3 years. The most common side effect was generalized edema. The other side effects were whitening of skin and rash . 2 patients suffered dyspnea on exertion and assessed with echocardiogram showing reduced ejection fraction. Dose adjustment was done to these patients. 1 patient was found to have liver function derangement.Table:
414P
Tumour Profile | ||
---|---|---|
Tumour site distribution | No | Percentange |
small intestine | 37 | 51 |
Stomach | 17 | 23 |
Colon and rectum | 10 | 14 |
Extra Gastrointestinal Tract | 9 | 12 |
Tumour sizes distribution | ||
< 10 cm | 24 | 33 |
10-20 cm | 41 | 56 |
>20 cm | 8 | 11 |
Tumour stages distribution | ||
Stage I | 9 | 12 |
Stage II | 13 | 18 |
Stage III | 35 | 48 |
Stage IV | 16 | 22 |
NIH risk distribution | ||
Low | 6 | 8 |
Intermediate | 6 | 8 |
High | 61 | 84 |
Conclusions
This study showed most patients presented with larger tumour sizes, high NIH risk and small intestine. Those who received imatinib up to 3 years had low rate of recurrence and well tolerated.
Clinical trial identification
Editorial acknowledgement
It would not have been possible without the guidance of our professors and co-authors who contributed their valuable expertise to the concepts displayed in this abstract.
Legal entity responsible for the study
Medical Oncology, Yangon General Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
258P - Assessment of sexual health in patients treated for ovarian cancer
Presenter: Renu Madan
Session: Poster display session
Resources:
Abstract
259P - The BOT patients fail to benefit from surgical staging procedures in prognosis and fertility outcomes: A retrospective analysis
Presenter: Li Na
Session: Poster display session
Resources:
Abstract
260P - Malignant ovarian germ cell tumours (MOGCT): Treatment results of 149 pts
Presenter: Dzhennet Chekini
Session: Poster display session
Resources:
Abstract
261P - Ovarian germ cell tumours - challenges and outcomes from a tertiary care centre in South India
Presenter: Vishnu Sreedath
Session: Poster display session
Resources:
Abstract
262P - Gestational trophoblastic tumours: Experience of the medical oncology department Hassan II University Hospital-Morocco about 29 cases
Presenter: Karima Oualla
Session: Poster display session
Resources:
Abstract
263TiP - ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled phase III study of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
264TiP - ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA¬-nonmutated advanced epithelial ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
265TiP - KEYNOTE-826: A phase III randomized study of chemotherapy with or without pembrolizumab for first-line treatment of persistent, recurrent, or metastatic cervical cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
271P - Comparison between CHOP like regimens and DAEPOCH with or without Rituximab in adult high grade B cell lymphoma NOS; A retrospective study from a tertiary cancer hospital in South India
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
272P - Melatonin increases the chemosensitivity of diffuse large Bell lymphoma cells to Epirubicin by inhibiting P-glycoprotein expression via the NF-κB pathway
Presenter: Xiuhua Sun
Session: Poster display session
Resources:
Abstract